AxoGen (AXGN)
(Delayed Data from NSDQ)
$6.63 USD
+0.11 (1.69%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.62 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
AxoGen (AXGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.00 | $17.00 | $11.00 | 99.39% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for AxoGen comes to $13.00. The forecasts range from a low of $11.00 to a high of $17.00. The average price target represents an increase of 99.39% from the last closing price of $6.52.
Analyst Price Targets (5 )
Broker Rating
AxoGen currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/6/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1/19/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
12/7/2023 | Canaccord Genuity | Caitlin Cronin | Strong Buy | Strong Buy |
10/16/2023 | SVB Securities | Michael Kratky | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $13.00 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 86 of 252 |
Current Quarter EPS Est: | -0.10 |